American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Earlier this week, the Financial Times reported activist investor Starboard Value had taken a stake in Becton and was pushing ...

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...

Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.

The company could announce the separation of the business, which consists of biosciences and diagnostic solutions, at the ...